Valneva SE VALN
Valneva SE (Nasdaq: VALN) is an infectious disease drug developer. Its lead program, LB6V (VLA15), is in Phase 3 for Prevention of Lyme disease. Its next catalyst on record is IXCHIQ: VLA1553-303 five-year seroresponse data (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: IXCHIQ — VLA1553-303 five-year seroresponse data (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IXCHIQ (VLA1553) | Chikungunya prevention | vaccine | Approved |
| LB6V (VLA15) | Lyme disease prevention | vaccine | Phase 3 |
| S4V2 | Shigellosis prevention | vaccine | Phase 2 |
| EBV vaccine | Epstein-Barr virus | vaccine | Pre-clinical |
| ETEC vaccine | Enterotoxigenic E. coli | vaccine | Pre-clinical |
Recent results and decisions
- Mar 23, 2026mixed Vaccine efficacy 73.2% (95% CI 15.8-93.5) in the first pre-specified analysis (primary endpoint), which missed the CI lower bound >20 criterion; second analysis 74.8% (95% CI 21.7-93.9) met it.
Fewer than anticipated Lyme disease cases were accrued over the study period, and the pre-determined statistical criterion (95% confidence interval lower bound >20) was not met in the first pre-specified analysis (primary endpoint).
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 infectious disease companies
- Gilead Sciences, Inc. GILD
- GSK plc GSK
- Moderna, Inc. MRNA
- Vaxcyte, Inc. PCVX
- Vir Biotechnology, Inc. VIR
- Novavax Inc NVAX
- Sinovac Biotech Ltd SVA
- CorMedix Inc. CRMD
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.